| Melissa Lee Longobardi, PA-C | |
|
571 Broad St, Central Falls, RI 02863-2837 | |
| (401) 864-0503 | |
| Not Available |
| Full Name | Melissa Lee Longobardi |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 571 Broad St, Central Falls, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376510172 | NPI | - | NPPES |
| 7009808 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | PA00269 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Lee Longobardi, PA-C 106 Common Fence Blvd, Portsmouth, RI 02871-5610 Ph: (401) 728-7556 | Melissa Lee Longobardi, PA-C 571 Broad St, Central Falls, RI 02863-2837 Ph: (401) 864-0503 |
News Archive
Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.
More than a decade before people with Huntington's disease show symptoms, they can exhibit abnormally high levels of an immune-system molecule called interleukin-6 (IL-6), which has led many researchers to suspect IL-6 of promoting the eventual neurological devastation associated with the genetic condition.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.
Despite the prevalence of the painful condition, women are fearful and frustrated with limited management options, according to Cedars-Sinai research published in the Journal of Urology.
› Verified 1 days ago